Surgical management of gastrointestinal endocrine tumours.
The surgical management of gastrointestinal endocrine tumours must involve a multidisciplinary approach. The importance of accurate diagnosis, rendering the patient safe, and, in our opinion, localizing the tumour(s) before embarking on surgery cannot be overemphasized. Surgery is the only available treatment for cure. Occult primary tumours are now rarely a problem with novel imaging techniques, which can also improve detection and hence clearance of local spread. Surgical management in extensive metastatic or multicentric disease is less rigidly defined, and is dependent on the endocrine syndrome. A better understanding of tumour pathology, for example in MEN 1, has not always simplified matters. An appreciation of the benefit of chemotherapy, use of somatostatin analogues and hepatic artery embolization are vital to target appropriate palliative surgery. Hepatic transplantation may have an increasing role in the future. Surgical strategies must adapt to new medical treatments. If therapeutically relevant, advances in tumour biology (for example somatostatin receptor subtypes and growth factors) will influence surgical strategies in the future.
Goldstone
A P
AP
Department of Endocrinology and Metabolism, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Scott-Coombes
D M
DM
Lynn
J A
JA
D003952:Diagnostic Imaging; D005260:Female; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008297:Male; D018761:Multiple Endocrine Neoplasia Type 1 / Q000401:mortality / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D009384:Paraneoplastic Endocrine Syndromes / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate